These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31567878)

  • 1. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms.
    Wu TH; Shen YC; Lee WC; Wang HJ; Chuang YC
    J Chin Med Assoc; 2020 Jan; 83(1):55-59. PubMed ID: 31567878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
    Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
    Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study.
    Karakus S; Musicki B; Burnett AL
    Int J Impot Res; 2022 Sep; 34(6):588-592. PubMed ID: 34215861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
    Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
    BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
    Shen YC; Wang HJ; Lee WC; Chen CH; Chuang YC
    Int J Clin Pract; 2020 Sep; 74(9):e13537. PubMed ID: 32438481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.
    Gubbiotti M; Giannantoni A; Cantaluppi S; Coluccia AC; Ghezzi F; Serati M
    BMC Urol; 2019 Jan; 19(1):7. PubMed ID: 30665388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
    Cho SY; Jeong SJ; Lee S; Kim J; Lee SH; Choo MS; Oh SJ
    Neurourol Urodyn; 2021 Jan; 40(1):286-294. PubMed ID: 33389776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
    Chen SF; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
    Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
    Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O180-O185. PubMed ID: 30565417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study.
    Lin CC; Kuo HC; Li JR; Chuang YC
    Int Neurourol J; 2023 Sep; 27(3):182-191. PubMed ID: 37798885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
    Chapple C; Khullar V; Nitti VW; Frankel J; Herschorn S; Kaper M; Blauwet MB; Siddiqui E
    Eur Urol; 2015 Jan; 67(1):11-14. PubMed ID: 25092537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.